iCAD Announces Exceptional Study Results Demonstrating Significant Advantages of Revolutionary Artificial Intelligence Technology for Digital Breast Tomosynthesis

NASHUA, N.H.and ATHENS, Greece,—iCAD, Inc.(NASDAQ: ICAD),a global medical technology leader providing innovative cancer detection and therapy solutions,today announced outstanding clinical results of its new, leading-edge digital breast tomosynthesis (DBT) cancer detection software. The study demonstrated significant positive results for clinical performance and workflow efficiency.

Medical societies issue new guideline for treating men with early-stage prostate cancer

The American Society for Radiation Oncology (ASTRO), American Society of Clinical Oncology (ASCO) and the American Urological Association (AUA) have issued a new guideline for treating men with early-stage prostate cancer. According to the three medical societies, hypofractionated external beam radiation therapy (EBRT) can shorten cancer treatments and provide more convenience to patients.